15 Results for "

NCI-H929 cells

" in MedChemExpress (MCE) Product Catalog:
Products (15)

15 Results for "NCI-H929 cells" in MCE Product Catalog:

3
3 Cited Publications
Cat. No.: HY-P9980
CAS No.: 2061894-48-0
Synonyms: GSK2857914

Research Areas:  

Cancer

Belantamab (GSK2857916) is a humanized IgG1 anti-BCMA/TNFRSF17 monoclonal antibody. Belantamab is linked to MMAF (HY-15579) through a non-cleavable ADC linker to synthesize the antibody-active molecule conjugate (ADC) Belantamab mafodotin (HY-P3239). After binding to BCMA on the surface of tumor cells, Belantamab mafodotin enters the cell through receptor-mediated endocytosis. After entering the cell, Belantamab mafodotin releases MMAF, blocks cell division by inhibiting tubulin polymerization, arrests the cell cycle and induces cell apoptosis. Belantamab can be used for the study of multiple myeloma, especially relapsed/refractory multiple myeloma .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-111594
CAS No.: 2244520-98-5
Purity:  99.43%
Target:  

PROTACs

Research Areas:  

Cancer

Homo-PROTAC cereblon degrader 1 is a highly selective cereblon (CRBN) PROTAC degrader. Homo-PROTAC cereblon degrader 1 induces self-directed ubiquitination and proteasomal degradation of CRBN. Homo-PROTAC cereblon degrader 1 blocks Pomalidomide (HY-10984)-induced degradation of IKZF1 and IKZF3. Homo-PROTAC cereblon degrader 1 antagonizes the growth inhibitory effect of Pomalidomide on multiple myeloma cells. Homo-PROTAC cereblon degrader 1 can be used in studies related to multiple myeloma .
loading...
    loading...
Cat. No.: HY-172085
CAS No.: 3099543-90-2
Research Areas:  

Cancer

SH514 is an orally active IRF4 inhibitor (IC50 = 2.63 μM). SH514 binds to the IRF4-DBD domain, thereby inhibiting the interaction of IRF4 protein with DNA (KD = 1.28 μM). SH514 can inhibit the proliferation of IRF4-high-expressing NCI-H929 and MM.1R cells, and displays no cytotoxicity for normal cells. SH514 significantly downregulates the expression of IRF4 downstream target genes concentration-dependently. SH514 inhibits the expression of cell cycle-related proteins CDC2, Cyclin B1, Cyclin D1, Cyclin E1, and CMYC in Multiple Myeloma cells. SH514 can induce DNA damage and increase the expression of γH2AX. SH514 effectively inhibits the proliferation of multiple myeloma tumors .
loading...
    loading...
Cat. No.: HY-144841
CAS No.: 2504235-67-8
Purity:  99.54%
Synonyms: CFT7455
Research Areas:  

Cancer

Cemsidomide (CFT7455) is a ubiquitin ligase pathway based IKZF1/3 (Ikaros/Aiolos) degrader with molecular glue activity . Cemsidomide has a GI50 of 0.05 nM for NCIH929.1 cells. Cemsidomide is used in the research of multiple myeloma (MM) .
loading...
    loading...
Cat. No.: HY-171754
Research Areas:  

Cancer

LM-305 is an anti-G protein-coupled receptor class 5 member D (GPRC5D) antibody-drug conjugate (ADC). LM-305 consists of Anti-GPRC5D Antibody (HY-P991197) and VcMMAE (HY-15575). LM-305 exhibits potent cytotoxicity against multiple myeloma cells (NCI-H929 and MM.1R) with IC50 values ranging from 0.1 to 0.3 nM. LM-305 can be used in the study of GPRC5D-related relapsed and refractory multiple myeloma (RRMM) .
loading...
    loading...
Cat. No.: HY-168615
CAS No.: 2991818-13-2
Research Areas:  

Cancer

MGD-28 is an orally effective cereblon-dependent molecular glue degrader that potently degrades CK1α, IKZF1, IKZF2, and IKZF3, with respective DC50 values of 7.8, 3.8, 56.3, and 7.1 nM. MGD-28 also induces the degradation of multiple novel substrate proteins including ZFP91, DTWD1, ZNFX1, MBD1, and MBD3 via a CRBN/Cullin- and proteasome-dependent mechanism. MGD-28 induces cell apoptosis. MGD-28 is used in the research of multiple myeloma, acute myeloid leukemia, diffuse large B-cell lymphoma, and related malignancies .
loading...
    loading...
Cat. No.: HY-175502
CAS No.: 2991818-12-1
Research Areas:  

Cancer

MGD-22, a molecular glue, is an orally active IKZF1/2/3 degrader with DC50 values of 8.33 nM, 9.91 nM, and 5.74 nM, respectively. MGD-22 exhibits extremely potent anti-proliferative activity against diverse hematological cancer cells. MGD-22 induces apoptosis in cancer cells. MGD-22 demonstrates potent anti-tumor efficacy in mice bearing NCI-H929 xenografts or WSU-DLCL-2 xenografts. MGD-22 can be used for the study of hematological cancers, including multiple myeloma (MM), acute myeloid leukemia (AML), and diffuse large B-cell lymphoma (DLBCL) .
loading...
    loading...
Cat. No.: HY-P11331
CAS No.: 1356828-49-3
Target:  

Proteasome

Research Areas:  

Others

Az-NC-002 is a Proteasome trypsin-like site (β2) and immunoproteasome β2i-specific active probe. Az-NC-002 has weak off-target effects with no significant inhibition for Cathepsin D (HY-P2750), but this inhibition reacts outside of the active site or influence on a small fraction of the enzyme .
loading...
    loading...
Cat. No.: HY-174445
CAS No.: 3107801-96-4
Research Areas:  

Cancer

C199 is a PROTAC degrader targeting PRMT4 (DC50 = 106 nM). C199 shows high selectivity for PRMT4 over other protein arginile methyltransferases. C199 exhibits strong cell degradation ability. C199 induces apoptosis in MM cell lines. C199 efficiently clears PRMT4 protein via the VHL-proteasome pathway. C199 has a relatively long half-life and shows strong anti-multiple myeloma (MM) tumor activity .
loading...
    loading...
Cat. No.: HY-144841A
CAS No.: 2504233-68-3
Purity:  98.52%
Synonyms: (Rac)-CFT7455
Target:  

Molecular Glues

Research Areas:  

Cancer

(Rac)-Cemsidomide ((Rac)-CFT7455) is the racemate of Cemsidomide (HY-144841) with antitumor activity . Cemsidomide is a ubiquitin ligase pathway Ikaros/Aiolos degrader with molecular glue activity. Cemsidomide has a GI50 of 0.05 nM for NCIH929.1 cells.
loading...
    loading...
Cat. No.: HY-P991462

Target:  

CD38

Research Areas:  

Cancer

GBR-1342 is a human bispecific antibody (bsAb) targeting CD38 & CD3. GBR-1342 inhibits the activity of Daudi, RAJI, RPMI8226, IM-9, and NCI-H929 cancer cell lines. GBR-1342 can be used in myeloma research .
loading...
    loading...
Cat. No.: HY-162780
Target:  

Bcl-2 Family

Research Areas:  

Cancer

Mcl-1-IN-19 (compound 26) binds to Mcl-1, with the Ki of 86 pM. Mcl-1-IN-19 inhibits growth in H929 cells with the GI of 43 nM .
loading...
    loading...
Cat. No.: HY-153952
CAS No.: 2757469-20-6
Immuno modulator-1 (compound 22) inhibits TNFα and IL-2 secretion in human peripheral blood mononuclear cells (hPBMC), with IC50 values of 4.7 and 26 nM, respectively. Immuno modulator-1 shows hERG potassium channel blocking effect, with Inhibitory percentage of 20% at 3 μM .
loading...
    loading...
Cat. No.: HY-111109R
CAS No.: 1628830-21-6
Research Areas:  

Cancer

EZM 2302 (Standard) is the analytical standard of EZM 2302 (HY-111109). This product is intended for research and analytical applications. EZM 2302 is a potent and orally active CARM1 inhibitor with an IC50 value of 6 nM. EZM 2302 shows antiproliferative activity and anti-tumor activity. EZM 2302 inhibits PABP1 and SMB expression .
loading...
    loading...
Cat. No.: HY-111594R
CAS No.: 2244520-98-5
Research Areas:  

Cancer

Homo-PROTAC cereblon degrader 1 (Standard) is the analytical standard of Homo-PROTAC cereblon degrader 1 (HY-111594). This product is intended for research and analytical applications. Homo-PROTAC cereblon degrader 1 is a highly selective cereblon (CRBN) PROTAC degrader. Homo-PROTAC cereblon degrader 1 induces self-directed ubiquitination and proteasomal degradation of CRBN. Homo-PROTAC cereblon degrader 1 blocks Pomalidomide (HY-10984)-induced degradation of IKZF1 and IKZF3. Homo-PROTAC cereblon degrader 1 antagonizes the growth inhibitory effect of Pomalidomide on multiple myeloma cells. Homo-PROTAC cereblon degrader 1 can be used in studies related to multiple myeloma .
loading...
    loading...
  • 1